Is Metropolis Healthcare the Best Stock in Its Sector? A Look at the Numbers
- October 13, 2026
- Posted by: Kunal Singla
- Category: Market
Metropolis Healthcare CMP Rs 541 (13 Oct 2026). Market cap Rs 11,150 Cr. ROE 12.56%. P/E 54.95x versus Industry P/E 62.56x.
Quick Answer
Metropolis Healthcare is one of the names investors compare when screening the Healthcare sector, built on a 12.56% return on equity and a P/E of 54.95x against an Industry P/E of 62.56x. Whether Metropolis Healthcare is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Metropolis Healthcare the best stock in its sector? The stock trades on the NSE at Rs 541 as of 13 October 2026, within its 52-week range of Rs 412.25 to Rs 609.05. Metropolis Healthcare Ltd, headquartered in Mumbai, is a diagnostics company that runs pathology laboratories and patient service centres across India and offers routine and specialised tests.
Metropolis Healthcare sits in the Healthcare sector, and its 12.56% ROE and 54.95x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Metropolis Healthcare
Metropolis Healthcare Ltd, headquartered in Mumbai, is a diagnostics company that runs pathology laboratories and patient service centres across India and offers routine and specialised tests. Routine and specialised tests, including for hospitals and healthcare providers, generate its revenue. The stock trades about 11 percent below its 52-week high and about 31 percent above its 52-week low. At a market capitalisation of Rs 11,150 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Metropolis Healthcare the Best Stock in Its Sector?
Metropolis Healthcare’s case rests on a lower valuation than its peers rather than on returns, with a 12.56% ROE. Metropolis Healthcare’s 54.95x P/E is below the 62.56x Industry P/E and the lowest in the peer table, but its 12.56% ROE is lower than both Dr. Lal PathLabs at 20.13% and Vijaya Diagnostic Centre at 18.07%.
| Metric | Metropolis Healthcare |
|---|---|
| CMP (NSE) | Rs 541.10 |
| 52-Week High / Low | Rs 609.05 / Rs 412.25 |
| Market Cap | Rs 11,150 Cr |
| P/E (TTM) vs Industry P/E | 54.95x vs 62.56x |
| P/B | 7.42 |
| ROE | 12.56% |
| EPS (TTM) | Rs 9.78 |
| Dividend Yield | 0.93% |
| Debt to Equity | 0.15 |
Compare Metropolis Healthcare Against Other Healthcare Sector Stocks
How Metropolis Healthcare Compares Against Its Healthcare Sector Peers
The table below sets Metropolis Healthcare against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Metropolis Healthcare | 11,150 | 54.95 | 12.56% | 0.15 |
| Dr. Lal PathLabs | 33,058 | 60.51 | 20.13% | 0.08 |
| Vijaya Diagnostic Centre | 14,969 | 79.85 | 18.07% | 0.44 |
| Peer average (2 companies) | – | 70.18 | 19.10% | 0.26 |
Against this peer set, Metropolis Healthcare’s 12.56% ROE is below the 19.10% peer average, and its P/E of 54.95x runs below the peer average of 70.18x. Metropolis Healthcare’s 54.95x P/E is below the 62.56x Industry P/E and the lowest in the peer table, but its 12.56% ROE is lower than both Dr. Lal PathLabs at 20.13% and Vijaya Diagnostic Centre at 18.07%.
What Makes Metropolis Healthcare Worth Watching in Healthcare
- Relative valuation: A 54.95x P/E is below Dr. Lal PathLabs at 60.51x and Vijaya Diagnostic Centre at 79.85x.
- Lower returns: A 12.56% ROE trails both diagnostic peers by several percentage points.
- Income: A dividend yield of 0.93% adds a modest income component.
Metropolis Healthcare Valuation: Is It Justified?
Metropolis Healthcare’s 54.95x P/E is below the 62.56x Industry P/E and the lowest in the peer table, but its 12.56% ROE is lower than both Dr. Lal PathLabs at 20.13% and Vijaya Diagnostic Centre at 18.07%. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Sun Pharma the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Metropolis Healthcare and other Healthcare sector stocks.
How to Track Metropolis Healthcare Before You Invest
Before deciding whether Metropolis Healthcare deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Metropolis Healthcare to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Metropolis Healthcare earns a place in the best stock in its sector conversation on the strength of a 12.56% ROE and a P/E of 54.95x against a 62.56x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Metropolis Healthcare the best stock in its sector?
Ans. Metropolis Healthcare has a 12.56% ROE and trades at 54.95x P/E against a 62.56x Industry P/E, and compares below the peer average ROE of 19.10% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Metropolis Healthcare?
Ans. Metropolis Healthcare was trading at Rs 541.10 on the NSE as of 13 October 2026, within its 52-week range of Rs 412.25 to Rs 609.05.
What sector does Metropolis Healthcare belong to?
Ans. Metropolis Healthcare is classified under the Healthcare sector on Univest.
How does Metropolis Healthcare compare to its sector peers on P/E?
Ans. Metropolis Healthcare’s P/E of 54.95x is below the 70.18x average of the 2 named peers compared in this article.
What is Metropolis Healthcare’s return on equity?
Ans. Metropolis Healthcare reported a return on equity of 12.56%, which is below the 19.10% average of its named peers in this comparison.
Should I invest in Metropolis Healthcare based on its sector position?
Ans. Metropolis Healthcare’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “Is Metropolis Healthcare the best stock in its sector?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Metropolis Healthcare has a 12.56% ROE and trades at 54.95x P/E against a 62.56x Industry P/E, and compares below the peer average ROE of 19.10% in this article’s named comparison, so the answer depends on what an investor is prioritising.”}}, {“@type”: “Question”, “name”: “What is the current share price of Metropolis Healthcare?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Metropolis Healthcare was trading at Rs 541.10 on the NSE as of 13 October 2026, within its 52-week range of Rs 412.25 to Rs 609.05.”}}, {“@type”: “Question”, “name”: “What sector does Metropolis Healthcare belong to?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Metropolis Healthcare is classified under the Healthcare sector on Univest.”}}, {“@type”: “Question”, “name”: “How does Metropolis Healthcare compare to its sector peers on P/E?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Metropolis Healthcare’s P/E of 54.95x is below the 70.18x average of the 2 named peers compared in this article.”}}, {“@type”: “Question”, “name”: “What is Metropolis Healthcare’s return on equity?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Metropolis Healthcare reported a return on equity of 12.56%, which is below the 19.10% average of its named peers in this comparison.”}}, {“@type”: “Question”, “name”: “Should I invest in Metropolis Healthcare based on its sector position?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Metropolis Healthcare’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.”}}]}
